| 17.32 0.19 (1.11%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.85  |
1-year : | 22.37 |
| Resists | First : | 17.85 |
Second : | 19.15 |
| Pivot price | 17.26  |
|||
| Supports | First : | 15.75 | Second : | 13.1 |
| MAs | MA(5) : | 17.63 |
MA(20) : | 17.15 |
| MA(100) : | 16.21 |
MA(250) : | 16.82 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 40.5 |
D(3) : | 51.5 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 35.34 | Low : | 12.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JANX ] has closed below upper band by 47.8%. Bollinger Bands are 1.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.67 - 17.79 | 17.79 - 17.89 |
| Low: | 16.73 - 16.88 | 16.88 - 17.01 |
| Close: | 17.09 - 17.32 | 17.32 - 17.54 |
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Thu, 15 Oct 2026
Janux Therapeutics, Inc. (JANX) stock price, news, quote and history - Yahoo Finance Australia
Wed, 14 Oct 2026
Janux Therapeutics, Inc. (JANX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 13 Oct 2026
Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now? - Yahoo Finance
Thu, 01 Oct 2026
Is First Patient Dosed Altering The Investment Case For Janux Therapeutics (JANX)? - Simply Wall Street
Wed, 23 Sep 2026
Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions - Simply Wall Street
Thu, 17 Sep 2026
Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 101.3 (%) |
| Shares Short | 5,680 (K) |
| Shares Short P.Month | 6,060 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.18 |
| Profit Margin | 0 % |
| Operating Margin | -308.7 % |
| Return on Assets (ttm) | -8.9 % |
| Return on Equity (ttm) | -10.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.64 |
| Sales Per Share | 0.39 |
| EBITDA (p.s.) | -2.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -10.57 |
| PEG Ratio | 0 |
| Price to Book value | 1.14 |
| Price to Sales | 44.12 |
| Price to Cash Flow | -25.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|